Article Text

PDF
Identifying progression predictors of breast ductal carcinoma in situ
  1. Joe Yeong1,2,
  2. Aye Aye Thike1,
  3. Puay Hoon Tan1,
  4. Jabed Iqbal1
  1. 1Division of Pathology, Singapore General Hospital, Singapore, Singapore
  2. 2Singapore Immunology Network (SIgN), Agency of Science, Technology and Research (A*STAR), Singapore, Singapore
  1. Correspondence to Dr Jabed Iqbal, Division of Pathology, Singapore General Hospital, 20 College Road, Academia, Level 10, Diagnostics Tower, Singapore 169856, Singapore; jabed.iqbal{at}singhealth.com.sg

Abstract

Ductal carcinoma in situ (DCIS) refers to neoplastic epithelial cells proliferating within the mammary ducts of the breast, which have not breached the basement membrane nor invaded surrounding tissues. Traditional thinking holds that DCIS represents an early step in a linear progression towards invasive ductal carcinoma (IDC). However, as only approximately half of DCIS cases progress to IDC, important questions around the key determinants of malignant progression need to be answered. Recent studies have revealed that molecular differences between DCIS and IDC cells are not found at the genomic level; instead, altered patterns of gene expression and post-translational regulation lead to distinct transcriptomic and proteomic profiles. Therefore, understanding malignant progression will require a different approach that takes into account the diverse tumour cell extrinsic factors driving changes in tumour cell gene expression necessary for the invasive phenotype. Here, we review the roles of the tumour stroma (including mesenchymal cells, immune cells and the extracellular matrix) and myoepithelial cells in malignant progression and make a case for a more integrated approach to the study and assessment of DCIS and its progression, or lack thereof, to invasive disease.

  • BREAST PATHOLOGY
  • TUMOUR MARKERS
  • TUMOUR IMMUNITY
  • BREAST CANCER

Statistics from Altmetric.com

Footnotes

  • Handling editor Cheok Soon Lee

  • Contributors All authors have substantial contributions to the conception, design and drafting the work.

  • Funding This article was funded by the A*STAR Biomedical Research Council, National Medical Research Council Stratified Medicine Programme Office (SMPO201302) awarded to PHT. JI is a recipient of the Transition Award from the Singapore National Medical Research Council (NMRC/TA/0041/2015).

  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.